Since mid-February, Meta Platforms has unveiled multi-year strategic partnerships with leading chipmakers Nvidia and AMD, underscoring an ambitious US$100 billion capital expenditure plan for 2026.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...
Hosted on MSN
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX)
Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from Neutral to Overweight. Analyst Price Forecast Suggests 37.89% Upside As of ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Tree recursion is a technique used to traverse a tree-like data structure by recursively visiting each node and its children. It’s widely used in computer science, particularly in algorithms that ...
RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...
Enhancements in clinical documentation, emotional quotient, audio handling, multilingual safety, orchestration, dialer, and integration features combined with advanced deep-thinking models to create a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results